ইকুয়েডর - স্পেনীয় - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

fresenius kabi oncology limited [in] india - cisplatino 1 mg - soluciÓn inyectable - cada ml contiene: cisplatino 1 mg

ভেনেজুয়েলা - স্পেনীয় - Instituto Nacional de Higiene

aspen venezuela, c.a. - telmisartan - hidroclorotiazida - tabletas - 80 mg - 12,5 mg

পিরু - স্পেনীয় - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

teva peru s.a. - dexametasona; - tableta - por tableta - dexametasona

ইউরোপীয় ইউনিয়ন - স্পেনীয় - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuria, paroxística - inmunosupresores selectivos - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

পিরু - স্পেনীয় - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

drogueria g & r s.r.ltda. - dexametasona; - tableta - por tableta - dexametasona

পিরু - স্পেনীয় - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

laboratorios farmaceuticos markos s.a. - laboratorio - dexametasona; - tableta - por tableta - - dexametasona

পিরু - স্পেনীয় - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

drogueria tobal s.a.c. - tableta - por tableta - dexametasona

পিরু - স্পেনীয় - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

laboratorios quilla pharma peru s.a.c. - droguerÍa - tableta - por tableta - - dexametasona

পিরু - স্পেনীয় - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

world drug pharmaceutical s.a.c. - droguerÍa - tableta - por tableta - - dexametasona

পিরু - স্পেনীয় - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

pharma-c s.a.c - droguerÍa - tableta - por tableta - - dexametasona